Lista de obras -

About the gut microbiome as a pharmacological target in atherosclerosis

artículo científico publicado en 2015

Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthy men.

artículo científico publicado en 2010

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

artículo científico publicado en 2016

Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.

artículo científico publicado en 2016

Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes

artículo científico publicado en 2015

Causality of small and large intestinal microbiota in weight regulation and insulin resistance

artículo científico publicado en 2016

Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.

artículo científico publicado en 2015

Distinct fecal and oral microbiota composition in human type 1 diabetes, an observational study.

artículo científico publicado en 2017

Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial

artículo científico publicado en 2014

Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide

artículo científico publicado en 2009

Ectopic Fat Storage in the Pancreas, Liver, and Abdominal Fat Depots: Impact on β-Cell Function in Individuals with Impaired Glucose Metabolism ⬇️

artículo científico publicado el 17 de noviembre de 2010

Effect of 3 Years of Treatment With Exenatide on Postprandial Glucagon Levels

artículo científico publicado en 2015

Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and its kidney clearance: post-hoc analyses of four clinical trials

artículo científico publicado en 2018

Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial

artículo científico publicado en 2020

Effects of DPP-4 inhibitor linagliptin versus sulfonylurea glimepiride on systemic haemodynamics in overweight patient with type 2 diabetes: a secondary analysis of an 8-week randomized controlled double-blind trial

artículo científico publicado en 2020

Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes

artículo científico publicado en 2020

Erratum. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care 2018;41:1543-1556

scientific article published on 20 August 2019

Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males

artículo científico publicado en 2015

GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion Independent of Nitric Oxide in Healthy Overweight Men.

artículo científico publicado en 2015

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes

artículo científico publicado en 2017

GLP-1 based therapies: clinical implications for gastroenterologists.

artículo científico publicado en 2016

GLP-1 receptor agonists, CKD, and eGFR trajectory

scientific article published on 01 October 2018

GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial

artículo científico publicado en 2016

Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment

artículo científico publicado en 2017

Glucagon-Like Peptide-1 Receptor Agonists: Beta-Cell Protection or Exhaustion?

artículo científico publicado en 2016

Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans.

artículo científico publicado en 2011

Glucocorticoid treatment impairs microvascular function in healthy men in association with its adverse effects on glucose metabolism and blood pressure: a randomised controlled trial

artículo científico publicado en 2013

Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy?

artículo científico

Glucosuria Interferes With Measurement of Effective Renal Plasma Flow Using para-Aminohippuric Acid, With a Focus on SGLT2 Inhibitors

artículo científico publicado en 2020

Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.

artículo científico publicado en 2016

High Prevalence of Intraductal Papillary Mucinous Neoplasms in Type 2 Diabetes Mellitus Patients

artículo científico publicado en 2020

Iloprost infusion prevents the insulin-induced reduction in skeletal muscle microvascular blood volume but does not enhance peripheral glucose uptake in type 2 diabetic patients

artículo científico publicado en 2018

Improving glycaemic control in type 2 diabetes: Stimulate insulin secretion or provide beta-cell rest?

artículo científico publicado en 2017

Intestinal Ralstonia pickettii augments glucose intolerance in obesity

artículo científico publicado en 2017

Islet-cell dysfunction induced by glucocorticoid treatment: potential role for altered sympathovagal balance?

artículo científico publicado en 2012

Light therapy for better mood and insulin sensitivity in patients with major depression and type 2 diabetes: a randomised, double-blind, parallel-arm trial

artículo científico publicado en 2015

Malignant cutaneous lesions

artículo científico publicado en 2015

Metabolic changes in type 2 diabetes are reflected in peripheral blood cells, revealing aberrant cytotoxicity, a viral signature, and hypoxia inducible factor activity

artículo científico publicado en 2015

Michaela Diamant, 11 April 1962-9 April 2014.

artículo científico publicado en 2014

Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial.

artículo científico publicado en 2016

Pancreatic Steatosis Is Not Associated With Exocrine Pancreatic Function in Overweight Type 2 Diabetes Patients.

artículo científico publicado en 2017

Pancreatic steatosis in humans: cause or marker of lipotoxicity?

artículo científico publicado en 2010

Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future

artículo científico publicado en 2004

Plasma uric acid and renal haemodynamics in type 2 diabetes patients

scientific article published on 12 September 2019

Pleiotropic effects of type 2 diabetes management strategies on renal risk factors.

artículo científico publicado en 2015

Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial

artículo científico

Prednisolone-induced beta cell dysfunction is associated with impaired endoplasmic reticulum homeostasis in INS-1E cells

artículo científico publicado en 2011

Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

artículo científico publicado en 2016

Renal hemodynamic and protective effects of renoactive drugs in type 2 diabetes: interaction with SGLT2 inhibitors

artículo científico publicado en 2020

Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function

artículo científico publicado en 2020

Renal outcomes in CVOTs: keep calm and carry on

artículo científico publicado en 2018

Renal sinus fat and renal hemodynamics: a cross-sectional analysis

artículo científico publicado en 2019

Renoprotection in LEADER and EMPA-REG OUTCOME

artículo científico publicado en 2016

Renoprotection in diabetic kidney disease: can incretin-based therapies deliver?

artículo científico publicado en 2020

Role of Insulin-Stimulated Adipose Tissue Perfusion in the Development of Whole-Body Insulin Resistance

artículo científico publicado en 2017

Role of the Gut Microbiome in the Pathogenesis of Obesity and Obesity-Related Metabolic Dysfunction

artículo científico publicado en 2017

SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.

artículo científico publicado en 2017

SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise

artículo científico publicado en 2020

SGLT2 inhibition: a new era in renoprotective medicine?

artículo científico publicado en 2017

SGLT2 inhibitors' interaction with other renoactive drugs in type 2 diabetes patients: still a lot to learn

artículo científico publicado en 2019

Sarcoidosis-related hypercalcaemia due to production of parathyroid hormone-related peptide

artículo científico publicado en 2015

Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?

artículo científico publicado en 2019

The authors reply

artículo científico publicado en 2020

The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes

artículo científico publicado en 2014

The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients.

artículo científico publicado en 2016

The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis

artículo científico publicado en 2019

The osteoblast: Linking glucocorticoid-induced osteoporosis and hyperglycaemia? A post-hoc analysis of a randomised clinical trial

artículo científico publicado en 2018

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

scientific article published on 10 October 2019

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.

artículo científico publicado en 2016

Uncomplicated human type 2 diabetes is associated with meal-induced blood pressure lowering and cardiac output increase

artículo científico publicado en 2014

Understanding EMPA-REG OUTCOME

artículo científico publicado en 2015

Lista de obras de

About the gut microbiome as a pharmacological target in atherosclerosis

Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthy men.

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.

Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes

Causality of small and large intestinal microbiota in weight regulation and insulin resistance

Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.

Distinct fecal and oral microbiota composition in human type 1 diabetes, an observational study.

Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial

Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide

Ectopic Fat Storage in the Pancreas, Liver, and Abdominal Fat Depots: Impact on β-Cell Function in Individuals with Impaired Glucose Metabolism ⬇️

Effect of 3 Years of Treatment With Exenatide on Postprandial Glucagon Levels

Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and its kidney clearance: post-hoc analyses of four clinical trials

Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial

Effects of DPP-4 inhibitor linagliptin versus sulfonylurea glimepiride on systemic haemodynamics in overweight patient with type 2 diabetes: a secondary analysis of an 8-week randomized controlled double-blind trial

Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes

Erratum. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care 2018;41:1543-1556

Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males

GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion Independent of Nitric Oxide in Healthy Overweight Men.

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes

GLP-1 based therapies: clinical implications for gastroenterologists.

GLP-1 receptor agonists, CKD, and eGFR trajectory

GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial

Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment

Glucagon-Like Peptide-1 Receptor Agonists: Beta-Cell Protection or Exhaustion?

Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans.

Glucocorticoid treatment impairs microvascular function in healthy men in association with its adverse effects on glucose metabolism and blood pressure: a randomised controlled trial

Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy?

Glucosuria Interferes With Measurement of Effective Renal Plasma Flow Using para-Aminohippuric Acid, With a Focus on SGLT2 Inhibitors

Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.

High Prevalence of Intraductal Papillary Mucinous Neoplasms in Type 2 Diabetes Mellitus Patients

Iloprost infusion prevents the insulin-induced reduction in skeletal muscle microvascular blood volume but does not enhance peripheral glucose uptake in type 2 diabetic patients

Improving glycaemic control in type 2 diabetes: Stimulate insulin secretion or provide beta-cell rest?

Intestinal Ralstonia pickettii augments glucose intolerance in obesity

Islet-cell dysfunction induced by glucocorticoid treatment: potential role for altered sympathovagal balance?

Light therapy for better mood and insulin sensitivity in patients with major depression and type 2 diabetes: a randomised, double-blind, parallel-arm trial

Malignant cutaneous lesions

Metabolic changes in type 2 diabetes are reflected in peripheral blood cells, revealing aberrant cytotoxicity, a viral signature, and hypoxia inducible factor activity

Michaela Diamant, 11 April 1962-9 April 2014.

Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial.

Pancreatic Steatosis Is Not Associated With Exocrine Pancreatic Function in Overweight Type 2 Diabetes Patients.

Pancreatic steatosis in humans: cause or marker of lipotoxicity?

Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future

Plasma uric acid and renal haemodynamics in type 2 diabetes patients

Pleiotropic effects of type 2 diabetes management strategies on renal risk factors.

Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial

Prednisolone-induced beta cell dysfunction is associated with impaired endoplasmic reticulum homeostasis in INS-1E cells

Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Renal hemodynamic and protective effects of renoactive drugs in type 2 diabetes: interaction with SGLT2 inhibitors

Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function

Renal outcomes in CVOTs: keep calm and carry on

Renal sinus fat and renal hemodynamics: a cross-sectional analysis

Renoprotection in LEADER and EMPA-REG OUTCOME

Renoprotection in diabetic kidney disease: can incretin-based therapies deliver?

Role of Insulin-Stimulated Adipose Tissue Perfusion in the Development of Whole-Body Insulin Resistance

Role of the Gut Microbiome in the Pathogenesis of Obesity and Obesity-Related Metabolic Dysfunction

SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.

SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise

SGLT2 inhibition: a new era in renoprotective medicine?

SGLT2 inhibitors' interaction with other renoactive drugs in type 2 diabetes patients: still a lot to learn

Sarcoidosis-related hypercalcaemia due to production of parathyroid hormone-related peptide

Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?

The authors reply

The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes

The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients.

The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis

The osteoblast: Linking glucocorticoid-induced osteoporosis and hyperglycaemia? A post-hoc analysis of a randomised clinical trial

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.

Uncomplicated human type 2 diabetes is associated with meal-induced blood pressure lowering and cardiac output increase

Understanding EMPA-REG OUTCOME